Spots Global Cancer Trial Database for previously treated myelodysplastic syndrome

Every month we try and update this database with for previously treated myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia	NCT00453388	Acute Myeloid L... de Novo Myelody... Fanconi Anemia Previously Trea...	Allogeneic Bone... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Total-Body Irra...	-	Fred Hutchinson Cancer Center
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	NCT00357565	Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo...	filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ...	- 3 Years	Masonic Cancer Center, University of Minnesota
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	NCT02921061	Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult...	Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	NCT02381548	Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult...	Adavosertib Belinostat Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	NCT02553941	Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo...	Azacitidine Ibrutinib	18 Years -	University of California, Davis
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	NCT00027820	Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child...	Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M...	-	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT02890329	Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo...	Decitabine Ipilimumab	18 Years -	National Cancer Institute (NCI)
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT02044796	Acute Biphenoty... de Novo Myelody... Previously Trea... Recurrent Adult... Untreated Adult... Secondary Acute...	Cladribine Cytarabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00313586	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	Azacitidine Entinostat Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome	NCT01624805	Aplastic Anemia de Novo Myelody... Myelodysplastic... Previously Trea...	Anti-Thymocyte ... Cyclosporine Filgrastim Methylprednisol... Pegfilgrastim	18 Years -	M.D. Anderson Cancer Center
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT01130506	Previously Trea... Recurrent Adult... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult...	Cytarabine Decitabine Laboratory Biom... Pharmacological... Vorinostat	18 Years - 59 Years	National Cancer Institute (NCI)
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome	NCT01624805	Aplastic Anemia de Novo Myelody... Myelodysplastic... Previously Trea...	Anti-Thymocyte ... Cyclosporine Filgrastim Methylprednisol... Pegfilgrastim	18 Years -	M.D. Anderson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT01757639	Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult... Secondary Myelo...	Ipilimumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	NCT03146871	Acute Myeloid L... Chronic Myelomo... Previously Trea... Recurrent Acute... Recurrent Adult...	Azacitidine Decitabine Laboratory Biom... Pharmacological... Recombinant Eph...	18 Years -	University of Southern California
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS	NCT02921061	Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult...	Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	NCT00313586	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	Azacitidine Entinostat Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	NCT00789776	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Diffuse Large B... Previously Trea... Recurrent Chron... Recurrent Chron... Recurrent Indol... Recurrent Mantl... Recurrent Plasm... Recurrent Small... Refractory Chro... Refractory Hodg... Refractory Plas... Refractory Smal... Waldenstrom Mac...	Allogeneic Bone... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Mycophenolate M... Natural Killer ... Tacrolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT02044796	Acute Biphenoty... de Novo Myelody... Previously Trea... Recurrent Adult... Untreated Adult... Secondary Acute...	Cladribine Cytarabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent	NCT03146871	Acute Myeloid L... Chronic Myelomo... Previously Trea... Recurrent Acute... Recurrent Adult...	Azacitidine Decitabine Laboratory Biom... Pharmacological... Recombinant Eph...	18 Years -	University of Southern California
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome	NCT02553941	Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo...	Azacitidine Ibrutinib	18 Years -	University of California, Davis
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01664897	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Alkylating Agen... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult...	Erlotinib Hydro... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT01130506	Previously Trea... Recurrent Adult... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult...	Cytarabine Decitabine Laboratory Biom... Pharmacological... Vorinostat	18 Years - 59 Years	National Cancer Institute (NCI)
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT02890329	Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo...	Decitabine Ipilimumab	18 Years -	National Cancer Institute (NCI)
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT01757639	Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Previously Trea... Recurrent Adult... Secondary Myelo...	Ipilimumab Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	NCT02083250	Acute Lymphobla... Acute Myeloid L... Allogeneic Hema... Myelodysplastic... Previously Trea... Recurrent Acute... Recurrent Acute...	Allogeneic Bone... Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Fludarabine Pho... Peripheral Bloo... Pharmacological... Vorinostat	- 60 Years	M.D. Anderson Cancer Center
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT01729845	Previously Trea... Recurrent Adult...	Cytarabine Decitabine Etoposide Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant	NCT02083250	Acute Lymphobla... Acute Myeloid L... Allogeneic Hema... Myelodysplastic... Previously Trea... Recurrent Acute... Recurrent Acute...	Allogeneic Bone... Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Fludarabine Pho... Peripheral Bloo... Pharmacological... Vorinostat	- 60 Years	M.D. Anderson Cancer Center
Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome	NCT03359460	Myelodysplastic... Previously Trea... Refractory High... Secondary Myelo... Therapy-Related...	Ibrutinib Lenalidomide	18 Years -	University of California, Davis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: